We are live on ! Find out more
BNGO icon

Bionano Genomics

140 hedge funds and large institutions have $146M invested in Bionano Genomics in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 44 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more call options, than puts

Call options by funds: $6.56M | Put options by funds: $2.96M

29% more capital invested

Capital invested by funds: $114M → $146M (+$32.9M)

0% less ownership

Funds ownership: 0.05%0.05% (-0%)

2% less funds holding

Funds holding: 143140 (-3)

15% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 20

23% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 44

Holders
140
Holders Change
-3
Holders Change %
-2.1%
% of All Funds
2.41%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
17
Increased
34
Reduced
44
Closed
20
Calls
$6.56M
Puts
$2.96M
Net Calls
+$3.6M
Net Calls Change
+$2.37M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$39.6M +$1.31M +993 +3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$28.8M +$243K +184 +0.7%
State Street
3
State Street
Massachusetts
$17.4M +$2.35M +1,779 +13%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$9.63M +$239K +181 +2%
Morgan Stanley
5
Morgan Stanley
New York
$6.12M +$690K +522 +10%
Northern Trust
6
Northern Trust
Illinois
$4.83M +$19.8K +15 +0.3%
Charles Schwab
7
Charles Schwab
California
$3.88M +$79.3K +60 +2%
Mitsubishi UFJ Asset Management
8
Mitsubishi UFJ Asset Management
Japan
$2.76M -$23.8K -18 -0.7%
Renaissance Technologies
9
Renaissance Technologies
New York
$2.58M -$4.95M -3,747 -61%
Mirae Asset Global Investments
10
Mirae Asset Global Investments
South Korea
$2.49M +$342K +259 +13%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$2.42M +$209K +158 +8%
Citadel Advisors
12
Citadel Advisors
Florida
$2.21M -$1.77M -1,340 -40%
N
13
Nuveen
North Carolina
$1.92M -$10.6K -8 -0.5%
Goldman Sachs
14
Goldman Sachs
New York
$1.66M +$342K +259 +21%
BNP Paribas Financial Markets
15
BNP Paribas Financial Markets
France
$1.55M -$89.8K -68 -5%
Swiss National Bank
16
Swiss National Bank
Switzerland
$1.25M
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$1M -$197K -149 -14%
Bank Julius Baer & Co
18
Bank Julius Baer & Co
Switzerland
$936K -$1.42M -1,078 -56%
RhumbLine Advisers
19
RhumbLine Advisers
Massachusetts
$835K +$80.6K +61 +9%
IA
20
Inspire Advisors
Idaho
$733K -$5.29K -4 -0.6%
AllianceBernstein
21
AllianceBernstein
Tennessee
$695K
Two Sigma Investments
22
Two Sigma Investments
New York
$694K -$712K -539 -46%
California State Teachers Retirement System (CalSTRS)
23
California State Teachers Retirement System (CalSTRS)
California
$667K -$23.8K -18 -3%
UBS AM
24
UBS AM
Illinois
$624K +$1.32K +1 +0.2%
D.E. Shaw & Co
25
D.E. Shaw & Co
New York
$511K +$589K +446 +2,347%

BNGO Hedge Fund Activity: Q3 2022 in Review

140 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Bionano Genomics (BNGO) for Q3 2022, worth a combined $146M — up 29% from $114M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of BNGO and 17 opened new positions — a net loss of 3 holders — while 44 trimmed existing stakes and 34 added.

The largest buyer was State Street, adding an estimated $2.35M. The largest seller was Renaissance Technologies, cutting an estimated $4.95M.

  • 140 institutional investors held Bionano Genomics (BNGO) as of Q3 2022, down from 143 in Q2 2022.
  • Funds reported $146M of Bionano Genomics stock for Q3 2022, up 29% quarter-over-quarter.
  • 17 funds opened new Bionano Genomics positions in Q3 2022 and 20 closed out, a net change of -3 holders.
  • The largest Bionano Genomics buyer in Q3 2022 was State Street, an estimated $2.35M added.
  • The largest Bionano Genomics seller in Q3 2022 was Renaissance Technologies, an estimated $4.95M sold.

Based on aggregated 13F filings for Q3 2022.